BRII-B

2137
1.0204.23% ( -0.045 )
Delay Closed: Nov 16, 16:08:11

Overview

BRII-B (2137)

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The...

Open
1.035
High
1.065
Low
0.970
Prev. Close
1.065
Volume
1.73M
Turnover
1.75M
Avg Price
1.013
Bid/Ask Ratio
21.21%
Amplitude
8.92%
52wk High
1.880
Volume Ratio
4.47
Turnover Ratio
0.24%
52wk Low
0.815
HK Mkt Cap
733.63M
Market CapHKD
733.63M
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.280
EPSDynamic
-0.322
EPSStatic
--
BVPS
3.55
P/B
0.29
HK Shares
719.25M
Dividend YieldTTM
--
DividendTTM
--
Shares
719.25M
Min lot size
500
Currency
HKD

BRII-B Analyst Rating

View more

Forecast & Rating

Mar 25, 2026
Price forecast
HK$2.0196.60%
Forecast & RatingHold
1analysts
  • Strong buy0.00%
  • Buy0.00%
  • Hold100.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Brii Biosciences (2137.HK) failed to hold onto gains after Phase 2b ENRICH data showed 32.4% HBsAg loss at 24 weeks, trading at HKD1.050, down 1.4% from the previous close of HKD1.065; it opened at the HKD1.065 high, fell to HKD0.970 in the afternoon session and rebounded to HKD1.025 late in the day, leaving a wide HKD0.970-HKD1.065 range on about 1.71 million shares and HKD1.73 million turnover. The rebound trimmed the intraday decline, but the stock remained below the previous close. AASLD 2026 late-breaking data supported the BRII-179-based priming and enrichment strategy, yet latest news showed the shares fell as much as 6% intraday. The company has repeatedly disclosed share buybacks, while Q2 2026 net loss was HKD58.08 million, narrowing 28.41% year on year, and EPS was -HKD0.0791, improving 29.47%; operating loss was HKD87.15 million, narrowing 8.87%. At HKD1.050, the stock is 44.74% below its 52-week high of HKD1.9, down 26.06% year to date, but above its MA20 of 0.987 and MA60 of 0.929, with a PB of 0.300 and market capitalization of HKD755 million. Though the hepatitis B data and buybacks have not yet led to sustained volume expansion.

  2. Nov, 4

    The stock opened at HK$0.980, slipped to HK$0.970 at 11:58, then climbed through the afternoon to a HK$1.020 high at 15:20 and closed at HK$1.010, roughly 3% above the morning open, on 1.017 million shares and about HK$1.02 million turnover at an average of HK$1.0024, with volume following the upward drift. The bid was underpinned by a near-daily buyback programme: 302,500 shares repurchased for HK$302,100 on 3 November, 283,000 shares on 30 October and 255,000 shares on 28 October, with disclosures on almost every trading day since late October, plus an equity disclosure filing on 2 November. On positioning, the stock is still down 27.82% year to date and 46.05% below its 52-week high of HK$1.90, yet it now sits above the MA20 of HK$0.912 and MA60 of HK$0.920 and 25.77% above the 52-week low of HK$0.815; market value is HK$738.9 million, P/B 0.29 and P/E negative. Though turnover of roughly HK$1.02 million and a 0.14% turnover rate point to thin liquidity.

  3. Nov, 3

    Brii Biosciences (2137.HK) spiked and faded: it opened at HK$1.080, then buying dried up, the shares slid to HK$0.975 by 11:07 BJ and settled at HK$0.980, down 2.49% from the prior close of HK$1.005 on a thin 0.11% turnover rate. Buybacks have run almost daily since mid-October, including 283,000 shares for HK$274,400 on 30 October and 62,500 shares for HK$62,300 on 2 November, yet they have not cleared selling pressure around the HK$1 line. Fundamentals remain pre-revenue: Q2 2026 revenue was blank while the net loss of HK$58.1 million narrowed 28.41% year on year and loss per share of HK$0.0791 improved 29.47%; the BRiSC siRNA platform launched in October has yet to generate income. The stock sits above its MA20 of 0.906 and MA60 of 0.920 but is down 30.99% year to date and 48.42% below the 52-week high of HK$1.9. It is nonetheless 20.25% above the 14 October low of HK$0.815.

  4. Oct, 26

    BRII Biosciences (2137.HK) opened low and closed high, dipping to HK$0.880 early before peaking at HK$0.955 by 11:55 BJ and settling at HK$0.945, up about 5.6% on 1.541 million shares worth HK$1.437 million. The bid followed a run of buybacks (78,000 shares on Oct 23, 54,500 on Oct 22) and the BRiSC dual-targeting siRNA platform launched in October. Fundamentals remain in loss-narrowing mode: Q2 2026 EPS was -HK$0.0791 with a net loss of HK$58.08 million, improved about 28% year on year. Price positioning is still weak, down 33.45% YTD and 52.51% below the 52-week high of HK$1.99, though the shares sit above MA20 (0.874) and MA60 (0.916). However, with PB at 0.270 and market cap of HK$681.9 million, buybacks of only tens of thousands of Hong Kong dollars each offer limited actual support.

  5. Oct, 23

    Brii Biosciences reversed early weakness to close at the session high: after touching 0.855 at 11:28 BJ, it ran to 0.915 at 15:59 BJ and settled at 0.895, up 2.87% from 0.870 on about 743k shares. The move was anchored by steady buybacks — 54,500 shares for HK$49,000 on October 22 and 110,000 shares for HK$93,000 on October 13 — which support a thinly traded float, alongside the launch of the BRiSC™ dual-targeting siRNA platform. Fundamentals remain loss-making but improving: Q2 2026 EPS of -HK$0.0791 narrowed 29.47% yoy and the HK$58.1m net loss narrowed 28.41%, with PB at 0.25x. The price is back above its 20-day MA of 0.872 yet still under the 60-day MA of 0.916, down 36.97% YTD and 55.03% below the 52-week high of 1.99, though it sits 9.82% above the October 14 low of 0.815. While no revenue has been recorded and a profit inflection is not yet visible, buyback size remains small versus the HK$645.9m market cap.

News